Previous page 3.1.3.1.3.3. Malignant hyperthermia   79 / 795  Next page 3.1.3.1.4. Phases of clinical trials Return 3.1.3.1.3.3. Malignant hyperthermia
Notes
      3. Old stuff
          3.1. Old pharm stuff (pre 2009)
              3.1.3. Pharmacology
                  3.1.3.1. Pharmacology principles
                      3.1.3.1.3. Pharmacogenetics
                          3.1.3.1.3.3. Malignant hyperthermia
 3.1.3.1.3.3.1. Dantrolene 

Dantrolene

 

 

Each bottle contains

Dantrolene 20mg

Mannitol 3g (solubilising agent)

 

Dosage 1mg/kg, up to 10mg/kg

Average requirement = 3mg/kg

 

Side effects include

N&V

Muscle weakness

Prolongation of non-depolarising NMBDs

Previous page 3.1.3.1.3.3. Malignant hyperthermia Next page 3.1.3.1.4. Phases of clinical trials Return 3.1.3.1.3.3. Malignant hyperthermia
Table of contents  | Bibliography  | Index
Revised at 2007/02/02 01:02